1. Home
  2. ZION vs PRAX Comparison

ZION vs PRAX Comparison

Compare ZION & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zions Bancorporation N.A.

ZION

Zions Bancorporation N.A.

SELL

Current Price

$63.25

Market Cap

9.4B

Sector

Finance

ML Signal

SELL

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$244.64

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZION
PRAX
Founded
1873
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
8.3B
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
ZION
PRAX
Price
$63.25
$244.64
Analyst Decision
Hold
Strong Buy
Analyst Count
23
21
Target Price
$72.73
★ $650.00
AVG Volume (30 Days)
★ 1.4M
513.3K
Earning Date
10-19-2026
11-04-2026
Dividend Yield
★ 3.05%
N/A
EPS Growth
★ 21.41
N/A
EPS
★ 4.61
N/A
Revenue
★ $662,000,000.00
N/A
Revenue This Year
$5.90
N/A
Revenue Next Year
$2.31
$39,256.17
P/E Ratio
$13.67
★ N/A
Revenue Growth
★ 3.60
N/A
52 Week Low
$48.50
$154.46
52 Week High
$73.34
$392.70

Technical Indicators

Market Signals
Indicator
ZION
PRAX
Relative Strength Index (RSI) 45.15 28.57
Support Level $60.80 $238.77
Resistance Level $63.94 $356.02
Average True Range (ATR) 1.16 12.12
MACD 0.22 -1.84
Stochastic Oscillator 64.60 14.77

Price Performance

Historical Comparison
ZION
PRAX

About ZION Zions Bancorporation N.A.

Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: